Published in Eur J Neurosci on May 01, 2004
The GSK3 hypothesis of Alzheimer's disease. J Neurochem (2007) 3.16
Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity. Neuron (2008) 2.88
Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45
RAGE-dependent signaling in microglia contributes to neuroinflammation, Abeta accumulation, and impaired learning/memory in a mouse model of Alzheimer's disease. FASEB J (2009) 1.39
Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med (2006) 1.36
Hydrogen peroxide promotes Abeta production through JNK-dependent activation of gamma-secretase. J Biol Chem (2008) 1.27
Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Mol Psychiatry (2008) 1.08
Redox proteomic analysis of carbonylated brain proteins in mild cognitive impairment and early Alzheimer's disease. Antioxid Redox Signal (2010) 1.04
Quantitative proteomics analysis of phosphorylated proteins in the hippocampus of Alzheimer's disease subjects. J Proteomics (2011) 1.01
Activity-dependent p25 generation regulates synaptic plasticity and Aβ-induced cognitive impairment. Cell (2014) 1.00
Oxidative Stress and Mitochondrial Dysfunction in Down's Syndrome: Relevance to Aging and Dementia. Curr Gerontol Geriatr Res (2012) 0.98
Cognitive enhancement with rosiglitazone links the hippocampal PPARγ and ERK MAPK signaling pathways. J Neurosci (2012) 0.97
Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities. Mol Cell Biol (2005) 0.94
Relative resistance of Cdk5-phosphorylated CRMP2 to dephosphorylation. J Biol Chem (2008) 0.91
Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology (2013) 0.91
Modulation of GSK-3 as a Therapeutic Strategy on Tau Pathologies. Front Mol Neurosci (2011) 0.91
Postsynaptic Receptors for Amyloid-β Oligomers as Mediators of Neuronal Damage in Alzheimer's Disease. Front Physiol (2012) 0.89
Altered serine/threonine kinase activity in schizophrenia. Brain Res (2014) 0.88
Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiol Aging (2011) 0.85
Aberrant Wnt signaling pathway in medial temporal lobe structures of Alzheimer's disease. J Neural Transm (Vienna) (2015) 0.82
Is amyloid binding alcohol dehydrogenase a drug target for treating Alzheimer's disease? Curr Alzheimer Res (2013) 0.82
Cdk5 is a New Rapid Synaptic Homeostasis Regulator Capable of Initiating the Early Alzheimer-Like Pathology. Cereb Cortex (2015) 0.80
Enhancement of BACE1 Activity by p25/Cdk5-Mediated Phosphorylation in Alzheimer's Disease. PLoS One (2015) 0.80
Amphioxus expresses both vertebrate-type and invertebrate-type dopamine D(1) receptors. Invert Neurosci (2010) 0.79
Characterisation of AmphiAmR11, an amphioxus (Branchiostoma floridae) D2-dopamine-like G protein-coupled receptor. PLoS One (2013) 0.77
Characterisation of AmphiAmR4, an amphioxus (Branchiostoma floridae) α₂-adrenergic-like G-protein-coupled receptor. Invert Neurosci (2012) 0.77
p38 MAPK Inhibition Improves Synaptic Plasticity and Memory in Angiotensin II-dependent Hypertensive Mice. Sci Rep (2016) 0.76
Reduced cortical BACE1 content with one bout of exercise is accompanied by declines in AMPK, Akt, and MAPK signaling in obese, glucose-intolerant mice. J Appl Physiol (1985) (2015) 0.76
Characterization of Neuronal Tau Protein as a Target of Extracellular Signal-regulated Kinase. J Biol Chem (2016) 0.76
TNFAIP1 contributes to the neurotoxicity induced by Aβ25-35 in Neuro2a cells. BMC Neurosci (2016) 0.75
Characterisation of Signalling by the Endogenous GPER1 (GPR30) Receptor in an Embryonic Mouse Hippocampal Cell Line (mHippoE-18). PLoS One (2016) 0.75
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatr Blood Cancer (2015) 0.75
Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science (2007) 5.23
Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet (2003) 4.84
Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet (2006) 3.91
Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol (2006) 3.72
Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med (2006) 2.95
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet (2007) 2.54
Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. Nat Genet (2012) 2.45
Increased cell proliferation and neurogenesis in the adult human Huntington's disease brain. Proc Natl Acad Sci U S A (2003) 2.36
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proc Natl Acad Sci U S A (2013) 2.21
Phosphorylated TDP-43 in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (2009) 2.01
Modulating angiogenesis: the yin and the yang in ginseng. Circulation (2004) 1.86
Transcriptional neoteny in the human brain. Proc Natl Acad Sci U S A (2009) 1.78
Population-specific expression analysis (PSEA) reveals molecular changes in diseased brain. Nat Methods (2011) 1.70
A role for human brain pericytes in neuroinflammation. J Neuroinflammation (2014) 1.64
DNA instability in postmitotic neurons. Proc Natl Acad Sci U S A (2008) 1.61
Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res (2007) 1.50
Prefrontal GABA(A) receptor alpha-subunit expression in normal postnatal human development and schizophrenia. J Psychiatr Res (2010) 1.50
Metabolic changes in schizophrenia and human brain evolution. Genome Biol (2008) 1.39
Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice. Neurobiol Dis (2008) 1.38
Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med (2006) 1.36
Gene expression in the prefrontal cortex during adolescence: implications for the onset of schizophrenia. BMC Med Genomics (2009) 1.31
Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark Insights (2010) 1.30
The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One (2008) 1.29
The effect of neurodegenerative diseases on the subventricular zone. Nat Rev Neurosci (2007) 1.28
Assessment of the relationship between pre-chip and post-chip quality measures for Affymetrix GeneChip expression data. BMC Bioinformatics (2006) 1.24
Psychotic illness in people with Prader Willi syndrome due to chromosome 15 maternal uniparental disomy. Lancet (2002) 1.24
An ovine transgenic Huntington's disease model. Hum Mol Genet (2010) 1.24
High throughput lipidomic profiling of schizophrenia and bipolar disorder brain tissue reveals alterations of free fatty acids, phosphatidylcholines, and ceramides. J Proteome Res (2008) 1.24
Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem (2002) 1.24
Distinct neuroinflammatory profile in post-mortem human Huntington's disease. Neuroreport (2009) 1.23
Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci U S A (2002) 1.22
GPR105, a novel Gi/o-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function. Brain Res Mol Brain Res (2003) 1.20
Gene expression becomes heterogeneous with age. Curr Biol (2006) 1.18
Hepatocyte growth factor/scatter factor can induce angiogenesis independently of vascular endothelial growth factor. Arterioscler Thromb Vasc Biol (2003) 1.17
Quantification of proteins using data-independent analysis (MSE) in simple andcomplex samples: a systematic evaluation. Proteomics (2011) 1.17
The cellular composition and morphological organization of the rostral migratory stream in the adult human brain. J Chem Neuroanat (2008) 1.17
Cholinergic neuronal defect without cell loss in Huntington's disease. Hum Mol Genet (2006) 1.17
Gene expression profiles of metabolic enzyme transcripts in Alzheimer's disease. Brain Res (2006) 1.15
Clinical bioinformatics for complex disorders: a schizophrenia case study. BMC Bioinformatics (2009) 1.14
Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration. Ann Neurol (2004) 1.13
Further evidence for altered myelin biosynthesis and glutamatergic dysfunction in schizophrenia. Int J Neuropsychopharmacol (2007) 1.12
Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet (2009) 1.11
The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics. Antioxid Redox Signal (2010) 1.10
Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res (2007) 1.10
Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. J Neurosci (2010) 1.10
Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain (2010) 1.08
Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology (2011) 1.07
2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res (2007) 1.04
Quantitative polymerase chain reaction: validation of microarray results from postmortem brain studies. Biol Psychiatry (2004) 1.04
Analyzing the effects of psychotropic drugs on metabolite profiles in rat brain using 1H NMR spectroscopy. J Proteome Res (2009) 1.04
Localization of glycine receptors in the human forebrain, brainstem, and cervical spinal cord: an immunohistochemical review. Front Mol Neurosci (2009) 1.04
Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression. Ann N Y Acad Sci (2004) 1.03
The role of proteomics in depression research. Eur Arch Psychiatry Clin Neurosci (2009) 1.03
Striosomes and mood dysfunction in Huntington's disease. Brain (2006) 1.02
Immunohistochemical staining of post-mortem adult human brain sections. Nat Protoc (2006) 1.01
Altered T-cell function in schizophrenia: a cellular model to investigate molecular disease mechanisms. PLoS One (2007) 1.01
Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. Clin Exp Pharmacol Physiol (2007) 1.01
CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS One (2007) 0.99
Peripheral profiling analysis for bipolar disorder reveals markers associated with reduced cell survival. Proteomics (2010) 0.99
Functional regulation of P2X6 receptors by N-linked glycosylation: identification of a novel alpha beta-methylene ATP-sensitive phenotype. Mol Pharmacol (2004) 0.99
Assessing RNA quality in postmortem human brain tissue. Exp Mol Pathol (2007) 0.99
Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration. J Proteome Res (2012) 0.98
Systematic analysis of gene expression in human brains before and after death. Genome Biol (2005) 0.98
Neurogenesis in humans. Eur J Neurosci (2011) 0.98
Application and optimization of microarray technologies for human postmortem brain studies. Biol Psychiatry (2004) 0.97
Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease. J Neurochem (2007) 0.97
The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus. Neuropsychopharmacology (2011) 0.97
Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci (2010) 0.97
Neurogenesis and progenitor cells in the adult human brain: a comparison between hippocampal and subventricular progenitor proliferation. Dev Neurobiol (2012) 0.96
M-CSF increases proliferation and phagocytosis while modulating receptor and transcription factor expression in adult human microglia. J Neuroinflammation (2013) 0.96
Label-free LC-MS/MS quantitative proteomics for large-scale biomarker discovery in complex samples. J Sep Sci (2007) 0.96
Comparison of peripheral and central schizophrenia biomarker profiles. PLoS One (2012) 0.94
Metabolic profiling of plasma from discordant schizophrenia twins: correlation between lipid signals and global functioning in female schizophrenia patients. J Proteome Res (2006) 0.94
Increased tau phosphorylation on mitogen-activated protein kinase consensus sites and cognitive decline in transgenic models for Alzheimer's disease and FTDP-17: evidence for distinct molecular processes underlying tau abnormalities. Mol Cell Biol (2005) 0.94
Signalling pathways influencing basal and H(2)O(2)-induced P-glycoprotein expression in endothelial cells derived from the blood-brain barrier. J Neurochem (2003) 0.93
Distinct molecular phenotypes in male and female schizophrenia patients. PLoS One (2013) 0.93
Identification of N-glycosylation changes in the CSF and serum in patients with schizophrenia. J Proteome Res (2010) 0.92
Extracellular signal-regulated kinase involvement in human astrocyte migration. Brain Res (2007) 0.92
Analysis of the human pituitary proteome by data independent label-free liquid chromatography tandem mass spectrometry. Proteomics (2011) 0.92
Insoluble TATA-binding protein accumulation in Huntington's disease cortex. Brain Res Mol Brain Res (2002) 0.92
Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci (2012) 0.92
Targeting of mitogen-activated protein kinases and phosphatidylinositol 3 kinase inhibits hepatocyte growth factor/scatter factor-induced angiogenesis. Circulation (2003) 0.91
The transcription factor PU.1 is critical for viability and function of human brain microglia. Glia (2013) 0.91
Molecular investigation of TBP allele length: a SCA17 cellular model and population study. Neurobiol Dis (2003) 0.90
ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Res (2010) 0.90
To label or not to label: applications of quantitative proteomics in neuroscience research. Proteomics (2012) 0.90
Antipsychotic treatment alters protein expression associated with presynaptic function and nervous system development in rat frontal cortex. J Proteome Res (2009) 0.90
N-terminal tripeptide of IGF-1 improves functional deficits after 6-OHDA lesion in rats. Neuroreport (2004) 0.90
The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia. BMC Res Notes (2012) 0.89
Neurobehavioral phenotype in Prader-Willi syndrome. Am J Med Genet C Semin Med Genet (2010) 0.89
Adult human glia, pericytes and meningeal fibroblasts respond similarly to IFNy but not to TGFβ1 or M-CSF. PLoS One (2013) 0.89
The rostral migratory stream and olfactory system: smell, disease and slippery cells. Prog Brain Res (2009) 0.88
Identification and characterization of a novel splice variant of the metabotropic glutamate receptor 5 gene in human hippocampus and cerebellum. Brain Res Mol Brain Res (2002) 0.88
Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies. Psychoneuroendocrinology (2012) 0.88
Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatry (2002) 0.88
How are treatment decisions made about artificial nutrition for individuals at risk of lacking capacity? A systematic literature review. PLoS One (2013) 0.88
Affinity depletion of plasma and serum for mass spectrometry-based proteome analysis. Methods Mol Biol (2013) 0.88